Related introduction of Subvenite (Lamotrigine): What kind of medicine is it used to treat?

Subvenite (Lamotrigine) is an approved anticonvulsant drug used primarily to treat epilepsy and bipolar disorder. As an oral suspension formulation of lamotrigine, Subvenite is designed for patients who require a liquid form, such as those who have difficulty swallowing tablets or who require individualized dosing.

In the treatment of epilepsy, Subvenite is suitable for patients 2 years old and above as auxiliary treatment. Its indications include partial-onset epilepsy, primary generalized tonic-clonic seizures (PGTC), and generalized seizures of Lennox-Gastaut syndrome. In addition, Subvenite can be used as monotherapy in patients 16 years of age and older, especially those with partial-onset epilepsy who are receiving medications such as carbamazepine, phenytoin, primidone, or sodium valproate, and are a viable option when switching to monotherapy.

In bipolar disorder, Subvenite is mainly used for the maintenance treatment of bipolar I disorder, aiming to delay the occurrence of acute mood attacks. However, caution is required when using this product, as this product is not recommended for the treatment of acute manic or mixed episodes, and its effectiveness in the treatment of acute mood episodes has not been established.

Lamotrigine was first approved in 1994 under the trade name Lamictal. After years of clinical application, it has been proven to have good efficacy in a variety of pharmaceutical preparations. In addition to oral suspension, Lamictal is also available as oral tablets, orally disintegrating tablets and extended-release tablets, all of which have been approved for generic versions.

Subvenite dosages are adjusted based on the patient's concomitant medications, indications, and age. The oral suspension is available in a concentration of 10 mg/ml. In addition, lamotrigine is also available in oral tablet form, including 25 mg, 100 mg, 150 mg and 200 mg in different dosages to meet different patient needs.

Reference materials:https://www.drugs.com/mtm/subvenite.html